MAGE—A和NY—ESO-1的表达与子宫颈癌临床病理特征及预后关系探讨

目的探讨子宫颈癌肿瘤组织中MAGE-A、NY-ESO-1的表达及与临床病理特征、预后关系。方法82例子宫颈癌患者分为两组。A组34例，FIGOⅠa1-Ⅰb1，接受根治性子宫切除术；B组48例，FIGOⅠb2-Ⅳa，接受新辅助化疗方案后行根治性子宫切除术。免疫组化法检测82例患者肿瘤组织中MAGE-A、NY-ESO-1的表达，并与患者临床病理特征及生存时间分析比较。结果 A组MAGE-A、NY-ESO-1阳性率分别为44.1%（15/34）和58.8%（20/34）。B组接受新辅助化疗前MAGE-A、NY-ESO-1的阳性率分别为56.3%（27/48）和54.2%（26/48），新辅助化疗后MAGE-A及NY-ESO-1的阳性率分别为53.5%（23/43）和55.8%（24/43）。A组≥2cm肿瘤MAGE-A、NY-ESO-1的阳性率高于〈2cm的肿瘤（P〈0.05）。不同N分期MAGE-A表达的阳性率差异也有统计学意义（P〈0.05）。MAGE-A阳性患者生存时间低于MAGE-A阴性者（P〈0.05）。结论 MAGE-A及NY-ESO-1在子宫颈癌中高表达，并且化疗药物对MAGE-A及NY-ESO-1的表达无影响。MAGE-A与肿瘤直径及淋巴结转移相关，可作为子宫颈癌患者的负性预后因子。

Objective To explore the relationship between the expression of MAGE-A,NY-ESO-1 and the clinical pathologic features and prognosis of cervical cancer and to observe the influence of neoadjuvant chemotherapy on the expression of MAGE-A and NY-ESO-1. Methods 82 cases were divided into two groups. Group A,34 patients of FIGO Ⅰa1-Ⅰb1, who received hysterectomy. Group B,48 patients of FIGO Ⅰb2-Ⅳa,who received neoadjuvant chemotherapy followed by hysterectomy. Immunohistochemistry was used to detect the expressions of MAGE-A,NY-ESO-1 in 82 cases of cervical cancer. Analysis the relationship between the expression of MAGE-A,NY-ESO-1 and pathological properties or prognosis. Results In group A,the positive expression reates of MAGE-A and NY-ESO-1 were 44.1% and 58.8%. In group B,the positive expression reates of MAGE-A and NY-ESO-1 were 56.3% and 54.2% before neoadjuvant chemotherapy. After neoadjuvant chemotherapy, the positive expression reates of MAGE-A and NY-ESO-1 were 53.5% and 55.8%. The positive expression reates of MAGE-A and NY-ESO-1 of tumor diameter ≥2cm were higher than 〈2cm in group A. The expression of MAGE-A was related with N stage. The survival time of patient with MAGE-A positive was lower than negative（P〈0.05）. Conclusion MAGE-A and NY-ESO-1 frequently express in cervical cancer. Drugs of chemotherapy were not influence the expression of MAGE-A and NY-ESO-1. MAGE-A is related with tumor diameter and lymph node metastases.